|
1
|
Alifrangis C and Seckl MJ: Genetics of
gestational trophoblastic neoplasia: an update for the clinician.
Future Oncol. 6:1915–1923. 2010.
|
|
2
|
Braunstein GD: Endocrine changes in
pregnancy. Williams Textbook of Endocrinology. 12th edition. Melmed
S, Polonsky KS, Larsen PR and Kronenberg HM: Saunders Elsevier;
Philadelphia, Pa: pp. 221–230. 2011
|
|
3
|
Lin KW, Yakymovych I, Jia M, Yakymovych M
and Souchelnytskyi S: Phosphorylation of eEF1A1 at Ser300 by TβR-I
results in inhibition of mRNA translation. Curr Biol. 20:1615–1625.
2010.
|
|
4
|
Sawai H, Yasuda A, Ochi N, et al: TGF-β
regulates invasive behavior of human pancreatic cancer cells by
controlling Smad expression. Arch Med Sci. 3:185–191. 2007.
|
|
5
|
Bandyopadhyay B, Han A, Dai J, et al:
TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin
cells according to distinct levels of TbetaRII expression. J Cell
Sci. 124(Pt 1): 19–24. 2011.
|
|
6
|
Huang F and Chen YG: Regulation of TGF-β
receptor activity. Cell Bios. 2:9–19. 2012.
|
|
7
|
Calone I and Souchelnytskyi S: Inhibition
of TGFβ signaling and its implications in anticancer treatments.
Exp Oncol. 34:9–16. 2012.
|
|
8
|
Galliher-Beckley AJ and Schiemann WP: Grb2
binding to Tyr284 in TbetaR-II is essential for mammary tumor
growth and metastasis stimulated by TGF-beta. Carcinogenesis.
29:244–251. 2008.
|
|
9
|
Gao Jin and Laurence JW: Potential
regeneration capacity of periodontal ligament with autocrine
production of transforming growth factor-beta 1 and its receptors.
Int J Dent Clin. 3:5–8. 2011.
|
|
10
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003.
|
|
11
|
Lu L, Wang J, Zhang F, et al: Role of SMAD
and non-SMAD signals in the development of Th17 and regulatory T
cells. J Immunol. 84:4295–4306. 2010.
|
|
12
|
Konrad L, Scheiber JA, Völck-Badouin E, et
al: Alternative splicing of TGF-betas and their high-affinity
receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal
new variants in human prostatic cells. BMC Genomics. 8:3182007.
|
|
13
|
Shinto O, Yashiro M, Kawajiri H, Shimizu
K, Shimizu T, Miwa A and Hirakawa K: Inhibitory effect of a TGFbeta
receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous
gastric cancer cells. Br J Cancer. 102:844–851. 2010.
|
|
14
|
Bakkebø M, Huse K, Hilden VI, Smeland EB
and Oksvold MP: TGF-β-induced growth inhibition in B-cell lymphoma
correlates with Smad1/5 signalling and constitutively active p38
MAPK. BMC Immunol. 11:572010.
|
|
15
|
Corrêa SA and Eales KL: The role of p38
MAPK and its substrates in neuronal plasticity and
neurodegenerative disease. J Signal Transduct. 2012:6490792012.
|
|
16
|
Whitmarsh AJ: A central role for p38 MAPK
in the early transcriptional response to stress. BMC Biol.
8:472010.
|
|
17
|
Wood CD, Thornton TM, Sabio G, Davis RA
and Rincon M: Nuclear localization of p38 MAPK in response to DNA
damage. Int J Biol Sci. 5:428–437. 2009.
|
|
18
|
Gangwal RP, Bhadauriya A, Damre MV, Dhoke
GV and Sangamwar AT: p38 mitogen-activated protein kinase
inhibitors: a review on pharmacophore mapping and QSAR studies.
Curr Top Med Chem. 13:1015–1035. 2013.
|
|
19
|
Krementsov DN, Thornton TM, Teuscher C and
Rincon M: The emerging role of p38 mitogen-activated protein kinase
in multiple sclerosis and its models. Mol Cell Biol. 33:3728–3734.
2013.
|
|
20
|
Mavropoulos A, Orfanidou T, Liaskos C, et
al: p38 MAPK signaling in pemphigus: implications for skin
autoimmunity. Autoimmune Dis. 2013:7285292013.
|
|
21
|
Xu Q, Tan Y, Zhang K and Li Y: Crosstalk
between p38 and Smad3 through TGF-β1 in JEG-3 choriocarcinoma
cells. Int J Oncol. 43:1187–1193. 2013.
|
|
22
|
Mincione G, Di Marcantonio MC, Artese L,
et al: Loss of expression of TGF-beta1, TbetaRI and TbetaRII
correlates with differentiation in humanoral squamous cell
carcinomas. Int J Oncol. 32:323–331. 2008.
|
|
23
|
Zhang YE: Non-Smad pathways in TGF-β
signaling. Cell Res. 19:128–139. 2009.
|
|
24
|
Chapnick DA, Warner L, Bernet J, Rao T and
Liu X: Partners in crime: TGFβ and MAPK pathways in cancer
progression. Cell Biosci. 1:422011.
|
|
25
|
Liu X, Gu W and Li X: HLA-G regulates the
invasive properties of JEG-3 choriocarcinoma cells by controlling
STAT3 activation. Placenta. 34:1044–1052. 2013.
|
|
26
|
Bian J, Li B, Zeng X, et al: Mutation of
TGF-β receptor II facilitates human bladder cancer progression
through altered TGF-β1 signaling pathway. Int J Oncol.
43:1549–1559. 2013.
|
|
27
|
Zhang P, Nakatsukasa H, Tu E and Kasagi S:
PARP-1 regulates expression of TGF-β receptors in T cells. Blood.
122:2224–2232. 2013.
|
|
28
|
Braunger BM, Pielmeier S, Demmer C, et al:
TGF-β signaling protects retinal neurons from programmed cell death
during the development of the mammalian eye. J Neurosci.
33:14246–14258. 2013.
|
|
29
|
Schedlich LJ, Yenson VM and Baxter RC:
TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in
human osteosarcoma cells. Mol Cell Endocrinol. 377:56–64. 2013.
|
|
30
|
Bhowmick NA, Zent R, Ghiassi M, McDonnell
M and Moses HL: Integrin beta 1 signaling is necessary for
transforming growth factor-beta activation of p38 MAPKand
epithelial plasticity. J Biol Chem. 276:46707–46713. 2001.
|
|
31
|
Daroqui MC, Vazquez P, Bal de Kier Joffé
E, Bakin AV and Puricelli LI: TGF-β autocrine pathway and MAPK
signaling promote cell invasiveness and in vivo
mammaryadenocarcinoma tumor progression. Oncol Rep. 28:567–575.
2012.
|
|
32
|
Gui T, Sun Y, Shimokado A and Muragaki Y:
The roles of mitogen-activated protein kinase pathways in
TGF-β-induced epithelial-mesenchymal transition. J Signal
Transduct. 2012:2892432012.
|
|
33
|
Jachec W, Foremny A, Domal-Kwiatkowska D,
et al: Expression of TGF-beta1 and its receptor genes (TbetaR I,
TbetaR II, and TbetaR III-betaglycan) in peripheral blood
leucocytes in patients with idiopathic pulmonary arterial
hypertension and Eisenmenger’s syndrome. Int J Mol Med. 21:99–107.
2008.
|
|
34
|
Galliher AJ and Schiemann WP: Src
phosphorylates Tyr284 in TGF-beta type II receptor and regulates
TGF-beta stimulation of p38 MAPK during breast cancer cell
proliferation and invasion. Cancer Res. 67:3752–3758. 2007.
|
|
35
|
Ohshima T and Shimotohno K: Transforming
growth factor-beta-mediated signaling via the p38 MAP kinase
pathway activates Smad-dependent transcription through SUMO-1
modification of Smad4. J Biol Chem. 278:50833–50842. 2003.
|
